FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308332634> ?p ?o ?g. }

• W4308332634 endingPage "70" @default.
• W4308332634 startingPage "70" @default.
• W4308332634 abstract "Most human fungal infections exhibit significant defensive oxidative stress responses, which contribute to their pathogenicity. An important component of these reactions is the activation of catalase for detoxification. To discover new antifungal chemicals, the antifungal activity of methanol extracts of Moringa oleifera from two commercial products (Akuanandi and Mas Lait) was investigated. The methanolic extracts’ activity against Sporothrix schenckii was determined using an assay for minimum inhibitory concentration (MIC) and minimum lethal concentration (MLC). The MIC concentrations varied between 0.5 μg/mL and 8 μg/mL. Akuanandi extract had the lowest MIC (0.5 μg/mL) and MLC (1 μg/mL) values. M. oleifera methanolic extracts were tested for catalase inhibition. The Ki values of the M. oleifera extract against S. schenckii catalase (SsCAT) was found to be 0.7 μg/mL for MOE-AK and 0.08 μg/mL for MOE-ML. Catalase’s 3D structure in SsCAT is unknown. The homology of SsCAT was modeled with an in silico study using a 3D structure from SWISS MODEL and validation the predicted 3D structure was carried out using PROCHECK and MolProbity. Docking simulations were used to analyze protein interactions using Pymol, PoseView, and PLIP. The results revealed that M. oleifera glucosinolates interacts with SsCAT. A molecular interaction analysis revealed two inhibitor compounds (glucosinalbin and glucomoringin) with high binding affinity to key allosteric-site residues. The binding energies revealed that glucosinalbin and glucomoringin bind with high affinity to SsCAT (docking energy values: −9.8 and −9.0 kcal/mol, respectively). The findings of this study suggest that glucosinolates derived from M. oleifera could be used instead of synthetic fungicides to control S. schenckii infections. We hope that the findings of this work will be valuable for developing and testing novel natural anti-sporothrix therapeutic agents in the future." @default.
• W4308332634 created "2022-11-11" @default.
• W4308332634 creator A5023485261 @default.
• W4308332634 creator A5030485223 @default.
• W4308332634 creator A5038219998 @default.
• W4308332634 creator A5044401843 @default.
• W4308332634 creator A5047998499 @default.
• W4308332634 creator A5074108339 @default.
• W4308332634 creator A5088515053 @default.
• W4308332634 date "2022-11-04" @default.
• W4308332634 modified "2023-09-27" @default.
• W4308332634 title "Anti-Sporotrichotic Activity, Lambert-W Inhibition Kinetics and 3D Structural Characterization of Sporothrix schenckii Catalase as Target of Glucosinolates from Moringa oleifera" @default.
• W4308332634 cites W1508052519 @default.
• W4308332634 cites W1547006808 @default.
• W4308332634 cites W172942410 @default.
• W4308332634 cites W1775749144 @default.
• W4308332634 cites W2008655265 @default.
• W4308332634 cites W2013025654 @default.
• W4308332634 cites W2020953719 @default.
• W4308332634 cites W2053152351 @default.
• W4308332634 cites W2061859855 @default.
• W4308332634 cites W2072268979 @default.
• W4308332634 cites W2080707979 @default.
• W4308332634 cites W2093819551 @default.
• W4308332634 cites W2098054235 @default.
• W4308332634 cites W2101286528 @default.
• W4308332634 cites W2142603650 @default.
• W4308332634 cites W2149525061 @default.
• W4308332634 cites W2151460035 @default.
• W4308332634 cites W2204552060 @default.
• W4308332634 cites W2279923506 @default.
• W4308332634 cites W2398478519 @default.
• W4308332634 cites W2518879474 @default.
• W4308332634 cites W2804822363 @default.
• W4308332634 cites W2915338872 @default.
• W4308332634 cites W2947030266 @default.
• W4308332634 cites W2950112481 @default.
• W4308332634 cites W2951439292 @default.
• W4308332634 cites W2955341169 @default.
• W4308332634 cites W2992152666 @default.
• W4308332634 cites W3036674808 @default.
• W4308332634 cites W3048909697 @default.
• W4308332634 cites W3092750903 @default.
• W4308332634 cites W3101411380 @default.
• W4308332634 cites W3172656319 @default.
• W4308332634 cites W3212359420 @default.
• W4308332634 cites W4210829608 @default.
• W4308332634 doi "https://doi.org/10.3390/scipharm90040070" @default.
• W4308332634 hasPublicationYear "2022" @default.
• W4308332634 type Work @default.
• W4308332634 citedByCount "0" @default.
• W4308332634 crossrefType "journal-article" @default.
• W4308332634 hasAuthorship W4308332634A5023485261 @default.
• W4308332634 hasAuthorship W4308332634A5030485223 @default.
• W4308332634 hasAuthorship W4308332634A5038219998 @default.
• W4308332634 hasAuthorship W4308332634A5044401843 @default.
• W4308332634 hasAuthorship W4308332634A5047998499 @default.
• W4308332634 hasAuthorship W4308332634A5074108339 @default.
• W4308332634 hasAuthorship W4308332634A5088515053 @default.
• W4308332634 hasBestOaLocation W43083326341 @default.
• W4308332634 hasConcept C159110408 @default.
• W4308332634 hasConcept C181199279 @default.
• W4308332634 hasConcept C185592680 @default.
• W4308332634 hasConcept C203014093 @default.
• W4308332634 hasConcept C2776836740 @default.
• W4308332634 hasConcept C2776872704 @default.
• W4308332634 hasConcept C2777250718 @default.
• W4308332634 hasConcept C2778979269 @default.
• W4308332634 hasConcept C31903555 @default.
• W4308332634 hasConcept C41685203 @default.
• W4308332634 hasConcept C55493867 @default.
• W4308332634 hasConcept C71240020 @default.
• W4308332634 hasConcept C71924100 @default.
• W4308332634 hasConcept C86803240 @default.
• W4308332634 hasConceptScore W4308332634C159110408 @default.
• W4308332634 hasConceptScore W4308332634C181199279 @default.
• W4308332634 hasConceptScore W4308332634C185592680 @default.
• W4308332634 hasConceptScore W4308332634C203014093 @default.
• W4308332634 hasConceptScore W4308332634C2776836740 @default.
• W4308332634 hasConceptScore W4308332634C2776872704 @default.
• W4308332634 hasConceptScore W4308332634C2777250718 @default.
• W4308332634 hasConceptScore W4308332634C2778979269 @default.
• W4308332634 hasConceptScore W4308332634C31903555 @default.
• W4308332634 hasConceptScore W4308332634C41685203 @default.
• W4308332634 hasConceptScore W4308332634C55493867 @default.
• W4308332634 hasConceptScore W4308332634C71240020 @default.
• W4308332634 hasConceptScore W4308332634C71924100 @default.
• W4308332634 hasConceptScore W4308332634C86803240 @default.
• W4308332634 hasIssue "4" @default.
• W4308332634 hasLocation W43083326341 @default.
• W4308332634 hasLocation W43083326342 @default.
• W4308332634 hasOpenAccess W4308332634 @default.
• W4308332634 hasPrimaryLocation W43083326341 @default.
• W4308332634 hasRelatedWork W205867798 @default.
• W4308332634 hasRelatedWork W2061250542 @default.
• W4308332634 hasRelatedWork W2120363545 @default.
• W4308332634 hasRelatedWork W2171033926 @default.
• W4308332634 hasRelatedWork W2398564609 @default.

• next